The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

被引:1308
|
作者
Cohn, Susan L. [1 ]
Pearson, Andrew D. J.
London, Wendy B.
Monclair, Tom
Ambros, Peter F.
Brodeur, Garrett M.
Faldum, Andreas
Hero, Barbara
Iehara, Tomoko
Machin, David
Mosseri, Veronique
Simon, Thorsten
Garaventa, Alberto
Castel, Victoria
Matthay, Katherine K.
机构
[1] Univ Chicago, Sect Pediat Hematol Oncol, Dept Pediat, Chicago, IL 60637 USA
关键词
PEDIATRIC-ONCOLOGY-GROUP; LOCALIZED NEUROBLASTOMA; FAVORABLE PROGNOSIS; NEURO-BLASTOMA; SURVIVAL TREES; CHROMOSOME; 1P; CRITERIA; AGE; AMPLIFICATION; PROGRESSION;
D O I
10.1200/JCO.2008.16.6785
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Because current approaches to risk classification and treatment stratification for children with neuroblastoma (NB) vary greatly throughout the world, it is difficult to directly compare risk-based clinical trials. The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification. Patients and Methods The statistical and clinical significance of 13 potential prognostic factors were analyzed in a cohort of 8,800 children diagnosed with NB between 1990 and 2002 from North America and Australia (Children's Oncology Group), Europe (International Society of Pediatric Oncology Europe Neuroblastoma Group and German Pediatric Oncology and Hematology Group), and Japan. Survival tree regression analyses using event-free survival (EFS) as the primary end point were performed to test the prognostic significance of the 13 factors. Results Stage, age, histologic category, grade of tumor differentiation, the status of the MYCN oncogene, chromosome 11q status, and DNA ploidy were the most highly statistically significant and clinically relevant factors. A new staging system (INRG Staging System) based on clinical criteria and tumor imaging was developed for the INRG Classification System. The optimal age cutoff was determined to be between 15 and 19 months, and 18 months was selected for the classification system. Sixteen pretreatment groups were defined on the basis of clinical criteria and statistically significantly different EFS of the cohort stratified by the INRG criteria. Patients with 5-year EFS more than 85%, more than 75% to <= 85%, >= 50% to <= 75%, or less than 50% were classified as very low risk, low risk, intermediate risk, or high risk, respectively. Conclusion By defining homogenous pretreatment patient cohorts, the INRG classification system will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world and the development of international collaborative studies.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 50 条
  • [1] The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
    Monclair, Tom
    Brodeur, Garrett M.
    Ambros, Peter F.
    Brisse, Herve J.
    Cecchetto, Giovanni
    Holmes, Keith
    Kaneko, Michio
    London, Wendy B.
    Matthay, Katherine K.
    Nuchtern, Jed G.
    von Schweinitz, Dietrich
    Simon, Thorsten
    Cohn, Susan L.
    Pearson, Andrew D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 298 - 303
  • [2] Update on the development of the international neuroblastoma risk group (INRG) classification schema
    Cohn, S. L.
    London, W. B.
    Monclair, T.
    Matthay, K. K.
    Ambros, P. F.
    Pearson, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force
    K K Matthay
    B Shulkin
    R Ladenstein
    J Michon
    F Giammarile
    V Lewington
    A D J Pearson
    S L Cohn
    British Journal of Cancer, 2010, 102 : 1319 - 1326
  • [4] The International Neuroblastoma Risk Groups (INRG): a preliminary report
    Castleberry, RP
    Pritchard, J
    Ambros, P
    Berthold, F
    Brodeur, GM
    Castel, V
    Cohn, SL
    De Bernardi, B
    Dicks-Mireaux, C
    Frappaz, D
    Haase, GM
    Haber, M
    Jones, DR
    Joshi, VV
    Kaneko, M
    Kemshead, JT
    Kogner, P
    Lee, REJ
    Matthay, KK
    Michon, JM
    Monclair, R
    Roald, BR
    Seeger, RC
    Shaw, PJ
    Shimada, H
    Shuster, JJ
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (12) : 2113 - 2116
  • [5] Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force
    Matthay, K. K.
    Shulkin, B.
    Ladenstein, R.
    Michon, J.
    Giammarile, F.
    Lewington, V.
    Pearson, A. D. J.
    Cohn, S. L.
    BRITISH JOURNAL OF CANCER, 2010, 102 (09) : 1319 - 1326
  • [6] International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
    Ambros, P. F.
    Ambros, I. M.
    Brodeur, G. M.
    Haber, M.
    Khan, J.
    Nakagawara, A.
    Schleiermacher, G.
    Speleman, F.
    Spitz, R.
    London, W. B.
    Cohn, S. L.
    Pearson, A. D. J.
    Maris, J. M.
    BRITISH JOURNAL OF CANCER, 2009, 100 (09) : 1471 - 1482
  • [7] International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
    P F Ambros
    I M Ambros
    G M Brodeur
    M Haber
    J Khan
    A Nakagawara
    G Schleiermacher
    F Speleman
    R Spitz
    W B London
    S L Cohn
    A D J Pearson
    J M Maris
    British Journal of Cancer, 2009, 100 : 1471 - 1482
  • [8] Neuroblastoma: validation of the INRG classification system in a small series
    E. Ramos Elbal
    A. M. Galera Miñarro
    M. E. Llinares Riestra
    M. Bermúdez Cortés
    J. L. Fuster Soler
    Clinical and Translational Oncology, 2019, 21 : 1776 - 1780
  • [9] Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project
    Vo, Kieuhoa T.
    DuBois, Steven G.
    Neuhaus, John
    Braunstein, Steve E.
    Weil, Brent R.
    Naranjo, Arlene
    Irtan, Sabine
    Balaguer, Julia
    Matthay, Katherine K.
    PEDIATRIC BLOOD & CANCER, 2022, 69 (09)
  • [10] Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project
    DuBois, Steven G.
    London, Wendy B.
    Zhang, Yang
    Matthay, Katherine K.
    Monclair, Tom
    Ambros, Peter F.
    Cohn, Susan L.
    Pearson, Andrew
    Diller, Lisa
    PEDIATRIC BLOOD & CANCER, 2008, 51 (05) : 589 - 592